Back to results
US 2003/0171273 A1Published application
Novel transcription factor, BP1
AssigneeThe George Washington University
InventorPatricia E. Berg
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe George Washington University
InventorPatricia E. Berg
Estimating the term…
An isolated DNA of SEQ ID NO:1 is provided that encodes the transcription factor BP1, which is believed to be a repressor of the β-globin gene. A host cell that is transformed with a vector that contains the DNA may be used to produce BP1. Vectors having a controllable promoter operably connected to the BPl open reading frame may be used to transform β-globin producing cells of patients with sickle cell anemia, thereby providing a treatment. Because BP1 is overexpressed in leukemia and breast cancer cells, acute myeloid leukemia, acute lymphocytic leukemia, and breast cancer can be screened for and diagnosed by determining whether BP1 is overexpressed in cell samples of patients who may have these conditions. An antisense DNA or RNA to the DNA encoding BP1 may be used as a treatment for acute myeloid leukemia, acute lymphocytic leukemia, and breast cancer.
An isolated DNA having SEQ ID NO:1, encoding BP1.
An antisense DNA or an antisense RNA complementary to the DNA having SEQ ID NO:1.
A method of treating sickle cell anemia, the method comprising the step of administering an effective amount of BP1 to a patient.
A method of screening or diagnosing acute myeloid leukemia or acute lymphocytic leukemia, the method comprising the steps of
A method of screening/diagnosis of breast cancer, the method comprising the steps of
An mRNA fragment encoding BP1 protein.
A polyclonal antibody to BP1.
A monoclonal antibody to BP1.
A composition comprising a set of PCR primers that amplifies a unique DNA molecule from a substrate of cDNA of mRNA that encodes for BP1.
Dependencies are inferred from the claim text.